Status:
COMPLETED
Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to learn if men with metastatic prostate cancer and rising Prostate Specific Antigen (PSA), who have been surgically castrated or are undergoing androgen deprivation with ...
Eligibility Criteria
Inclusion
- males, 18 or older
- proven advanced prostate cancer
- documented metastatic disease
- rising PSA levels
- castrate levels of testosterone
Exclusion
- symptomatic CNS (brain or spinal cord) metastasis
- medical condition which may increase the risk of toxicity
- any prior or ongoing anti-cancer medical therapy or immunotherapy for prostate cancer other than primary androgen deprivation agents
- unable to take oral medication
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT00385580
Start Date
January 1 2007
End Date
October 1 2010
Last Update
April 30 2013
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars Sinai Medical Center
Los Angeles, California, United States, 90048
2
University Of Chicago
Chicago, Illinois, United States, 60637
3
The Bunting Blaustein Cancer Research Building
Baltimore, Maryland, United States, 21231
4
Memorial Sloan-Kettering Cancer Center-Sidney Kimmel Center
New York, New York, United States, 10021